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ABSTRACT OF DISSERTATION 
OVERCOMING TREATMENT RESISTANCE IN HETEROGENEOUS TUMORS 
Most primary tumors are heterogeneous and are often composed of therapy-
sensitive and emerging therapy-resistant cancer cells. Rather unexpectedly, 
treatment of therapy-sensitive tumor cells in heterogeneous tumor 
microenvironments resulted in apoptosis of the therapy-resistant cancer cells. 
We identified a novel Par-4 amino-terminal fragment (PAF, which includes 
amino acids 1-131 of Par-4) that is produced and released by therapy-
sensitive cancer cells following therapy-induced caspase-dependent cleavage of 
the tumor suppressor Par-4. PAF caused paracrine apoptosis in therapy-resistant 
cancer cells. Unlike Par-4-inducible apoptosis, which is dependent on the cell 
surface GRP78 receptor, PAF produced cancer-selective apoptosis 
independent of cell surface GRP78 function. Par-4 contains a VASA segment at 
amino acids 68-73 that is involved in binding and degradation of Par-4 by 
ubiquitin ligases, resulting in the loss of its pro-apoptotic function. On the other 
hand, this VASA segment in PAF translocates selectively into cancer cells, binds 
to the ubiquitin ligase FBXO45, and releases FBXO45 bound Par-4 for cancer 
cell-specific apoptosis via activation of the FADD/caspase 8/caspase 3 pathway. 
Collectively, our findings identify a novel mechanism by which cancer 
therapeutics utilize tumor heterogeneity to overcome resistance in cancer cells.   
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CHAPTER ONE: INTRODUCTION 
Most tumors are phenotypically and functionally heterogeneous owing to their 
multi-clonal nature, genetic instability and tumor cell plasticity (Burrell et al., 
2013; Hanahan and Weinberg, 2011). Studies on tumor progression and 
response to therapy over the last few decades have indicated that primary 
tumors are usually responsive to the standard of care therapy aimed largely at 
reducing tumor bulk. However, therapy-resistant tumor cells emerge mainly at 
distant metastatic sites, and less frequently at the primary site, within a few years 
after the primary tumor has regressed (Schmitt et al., 2015). These observations 
indicate that a dynamic relationship exists between the treatment of primary 
tumors and emergence of resistant clones. In an effort to understand the 
mechanisms of tumor resistance to therapy, we are studying the relationship 
between therapy-sensitive and therapy-resistant tumor cells. Our studies 
indicated that therapy-resistant cancer cells undergo apoptosis if the therapy-
sensitive cancer cells in a heterogeneous tumor microenvironment are induced to 
undergo apoptosis. This paracrine effect of the therapy-sensitive tumor cells 
undergoing apoptosis was attributed to a novel, therapy-induced, caspase-
cleavage fragment of the tumor suppressor prostate apoptosis response-4 (Par-
4) protein.
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Apoptosis 
In most living systems cell death normally occurs through a series of controlled 
and highly regulated cell signaling events, rather than as a result of physical or 
mechanical damage. One of the most important mechanisms of cell death, and 
one that is observed across various species, is Apoptosis (also referred to as 
programmed cell death). The process of apoptosis is characterized by a 
sequence of defined events including shrinkage of cells, membrane blebbing and 
chromatin condensation (pyknosis) (Kerr et al., 1972). Apoptosis is an important 
physiological process as it plays an important role in normal tissue turnover and 
is essential for normal embryonic development. It often becomes deregulated in 
malignancies and can hinder cancer therapy. Mechanisms of apoptosis are 
broadly classified into two subtypes, the extrinsic or the death receptor mediated 
pathway and intrinsic or mitochondrial apoptotic pathways. The death receptor 
pathway is triggered by a number of ligands that bind to the cells that express the 
appropriate surface receptors and initiate a signaling cascade that induces cell 
death. The mitochondrial pathway on the other hand, is triggered when cells are 
under extreme stress conditions such as endoplasmic reticulum (ER) stress, 
extensive DNA damage or oxidative damage, which cannot be remedied by the 
in-built repair mechanisms. Certain cell types rely on specific growth factors or 
hormone stimulation in order to proliferate or maintain homeostasis. The absence 
of said growth factors/hormones for a certain time period can also trigger 
apoptosis in cells. 
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The process of apoptosis is orchestrated by a number of cysteine proteases 
called caspases. These enzymes are central to both death receptor and 
mitochondrial apoptosis. They can be broadly classified into two groups based on 
their location and function in the apoptotic cascade.  The apical caspases like 
caspase 8 and caspase 9 are called initiator caspases. They are produced as 
inactive zymogens which are comprised of a prodomain that is usually required 
for recruitment of the caspase to the site of activation, and a large and small 
subunit.  In the case of caspase 8 for example, signaling begins with an 
interaction between death receptors like Death Receptor 4 (DR4) or Death 
Receptor 5 (DR5) at the cell surface with its ligand TNF-related apoptosis-
inducing ligand (TRAIL). TRAIL upon binding to its receptor, recruits signal 
transduction complex FAS associated death domain (FADD) which binds to pro-
caspase 8 and activates it. Recruitment of the initiator caspase forces a change 
in conformation that brings their monomeric subunits in close proximity to form 
active sites.  Active caspase 8 proteolytically cleaves downstream caspases 
called effector or executioner caspases. This cleavage of the executioner 
caspases between their large and small subunit causes activation of these 
enzymes. In the extrinsic apoptotic pathway, caspase 8 cleaves caspase 3 
thereby activating it. The active caspase 3, which is an effector caspase, can 
further activate other caspases or a plethora of proteins often associated with 
vital physiological process. Proteolytic cleavage of such proteins results in 
cellular changes that ultimately lead to apoptosis. The mitochondrial pathway is 
triggered due to severe cellular stresses. It is the more commonly activated 
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apoptotic pathway and is triggered in response to oxidative or DNA damage or 
ER stress. The initiator caspase which plays a crucial role in the intrinsic 
apoptotic pathway is caspase 9. When the cell is under stress conditions an 
activation platform known as the apoptosome is assembled around the apoptotic 
protease-activating factor 1 (APAF1). Cytochrome c which, under normal 
conditions is found exclusively within the intermembrane region of the 
mitochondria is released from the mitochondria under apoptotic stimuli. The 
cytochrome c released into the cytoplasm interacts with Apaf1 and triggers ATP 
to ADP hydrolysis followed by oligomerization and activation of the apoptosome. 
This multimeric apoptosome recruits caspase 9 and activates it. Once caspase 9 
is activated it cleaves downstream caspases like caspase 3 resulting in apoptosis 
(Fesik, 2005; Green and Llambi, 2015; Lowe and Lin, 2000). There are a number 
of other proteins, such as the BCL2 family that regulates the apoptotic process. 
The BCL2 protein family is comprised of both pro- and anti-apoptotic proteins. 
Pro-apoptotic proteins like BAX and BAK which are members of the BCL2 protein 
family localize to the mitochondrial membrane in response to apoptotic signals 
and trigger cytochrome c release leading to caspase activation. The pro-
apoptotic BH3-only proteins function by promoting BAX and BAK oligomerization 
and activation, or by direct inhibition of the anti-apoptotic BCL2 proteins.  The 
inhibitors of apoptosis (IAPs) constitute an important part of the anti-apoptotic 
machinery within the cell, along with proteins such as BCL2 and BCL-XL. The 
overexpression of these proteins often plays a major role in resistance to cancer 
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therapy, poor prognosis and reduced survival in many cancers, making them 
attractive drug targets for cancer therapy (Fesik, 2005). 
Prostate Apoptosis Response-4 (Par-4) 
Par-4 is a leucine zipper domain containing protein that was first identified in 
prostate cancer cells and was later discovered to be ubiquitously expressed in 
diverse cell types and tissues. The identification of Par-4 was carried out using 
differential hybridization. In a seminal experiment, upon treatment with 
ionomycin, increased intracellular Ca2+ concentration ([Ca2+]i) in AT-3 androgen-
independent rat prostate cancer cells resulted in the induction of Par-4, which led 
to its identification as an immediate early apoptotic gene.  Par-4 expression was 
induced in the rat ventral prostate cells undergoing apoptosis in response to 
castration. On the other hand, a similar increase in Par-4 expression was not 
found in other tissues like the liver and kidney that are insensitive to 
castration/androgen ablation-induced apoptosis. It was observed that only 
activation of the apoptotic signaling pathway and not growth arrest, oxidative 
stress or necrosis, led to downstream upregulation of Par-4 (Sells et al., 1994).  
Identification of Par-4 
Two separate yeast two hybrid studies led to the discovery of human Par-4 as a 
binding partner to the tumor suppressor Wilm’s tumor1 (WT1) (Johnstone et al., 
1996) and atypical Protein Kinase C (aPKC) (Diaz-Meco et al., 1996). Par-4 has 
been shown to be expressed in a wide variety of tissues and species including 
6 
mammals and other vertebrates like birds, fish and Xenopus (El-Guendy and 
Rangnekar, 2003). The sequence of human, mouse and rat Par-4 show very high 
sequence homology with regards to both the DNA and protein. The extensive 
sequence conservation across vertebrates underlines the importance of Par-4 as 
an important player in the context of biology and evolution. 
Structure and Domains of Par-4 
The Par-4 gene is found on the minus strand of the unstable 12q21 region of the 
human chromosome (Johnstone et al., 1998) and encodes a protein of 340 
amino acids in humans, 332 amino acids in rats, and 333 amino acids in mice. 
The ubiquitously expressed Par-4 protein has several distinct domains and 100% 
conversation is observed among the functionally critical domains of Par-4 (El-
Guendy and Rangnekar, 2003). The domains that are known to be important for 
Par-4 function include a C-terminal Leucine Zipper (LZ) domain, two putative 
nuclear localization sequences NLS1 and NLS2 located at the N-terminus and 
the Selective for Apoptosis in Cancer (SAC) domain which is centrally located 
within Par-4. The 40 amino acid LZ domain contains five leucine repeats located 
at the carboxy terminal end of Par-4 is responsible for binding to most of its 
partner proteins via homo- or hetero-dimerization. Proteins such as Akt1 bind to 
the LZ domain result in the phosphorylation and subsequent inactivation of Par-4 
(Goswami et al., 2005). Other Par-4 partner proteins like WT1 (Johnstone et al., 
1996) and ζPKC (Diaz-Meco et al., 1996)  also bind to Par-4 through the LZ 
domain. 
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The two nuclear localization sequences NLS1 and NLS2 at the N-terminal end of 
Par-4 are highly conserved among humans, mice and rats. The NLS1 domain is 
a short 6 amino acid sequence followed by a bipartite NLS2 sequence further 
downstream. Studies showed that deletion of NLS1 had no effect on the 
translocation of Par-4 from the cytoplasm into the nucleus, whereas a ∆NLS2 
mutant of Par-4 was incapable of nuclear translocation which is necessary for the 
ability of Par-4 to inhibit NFκB and induce apoptosis (El-Guendy et al., 2003). 
The studies on Par-4 thus far have described the SAC domain as the critical 
domain required for the pro-apoptotic function of Par-4. SAC is a core domain 
that is 100% conserved across various mammals including rodents, humans and 
chimpanzee. SAC is 59 amino acids in length and contains the NLS2 sequence 
that enables its nuclear translocation. The domain derives its name from its 
ability to exclusively target cancer cells for apoptosis. When ectopically 
expressed this domain induces apoptosis specifically in cancer cells while 
leaving the normal cells unaffected. The ability of Par-4 to induce apoptosis in 
cancer cells is attributed to the SAC domain. The cancer selective nature of Par-
4 or SAC is due to the presence of a consensus site for PKA phosphorylation. 
PKA activity is often upregulated in a variety of cancers cells (Zhao and 
Rangnekar, 2008). 
In this dissertation, I am introducing the existence of another domain of Par-4 
that is pro-apoptotic in function and is naturally produced as a result of caspase 
cleavage. The domain is located between amino acids 1-131 and I have 
designated it as Par-4 Amino terminal Fragment (PAF). My aim is to demonstrate 
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that PAF is produced and released from therapy sensitive cells in response to 
chemotherapy/targeted therapy and it can induce apoptosis in the surrounding 
therapy-resistant cells.  
Apoptosis by Par-4 
The pro-apoptotic nature of Par-4 was made evident by its elevated expression in 
the granulosa cells of atretic ovarian follicles, dying neurons during neuronal 
development, and the involution of the tadpole tail. (El-Guendy and Rangnekar, 
2003). Its pro-apoptotic function was further corroborated when Par-4 was 
expressed in ductal cells of the prostate; that do not express Par-4 under normal 
conditions, but show Par-4 expression when they undergo apoptosis due to 
androgen ablation (Boghaert et al., 1997). Cell culture studies indicate that 
ectopic expression of Par-4 induces apoptosis in a wide range of cancers and 
this effect is brought about by the nuclear translocation of Par-4. The cyto-
protective effects of proteins like Bcl-xL and BCL2, and the lack of p53 or 
functional PTEN is overcome by the apoptotic action of Par-4. However, 
hormone-responsive  cancer cells and normal or immortalized cells are not 
sensitive to direct apoptosis by Par-4, but are instead sensitized to apoptotic 
signals like elevated intracellular Ca2+, tumor necrosis factor or exposure to UV 
or ionizing radiation (Chakraborty et al., 2001; El-Guendy et al., 2003; Nalca et 
al., 1999). The sensitization to apoptotic signals is attributed to the ability of Par-4 
to bind to ζPKC.  The accumulation and sequestration of Par-4 results from its 
inability to translocate to the nucleus due to phosphorylation by Akt1 (Goswami 
et al., 2005). The pro-apoptotic ability of Par-4 has been successfully translated 
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in-vivo by injection of Par-4 adenovirus into PC-3 tumors which caused 
significant tumor inhibition. The dramatic reduction in tumor volume was due to 
Par-4-induced apoptosis via Fas-FADD-caspase 8-caspase 3 pathway activation 
and inhibition of NF-κB dependent transcription. 
Thus, activation of the apoptotic signaling cascades or the downmodulation of 
cell survival pathways are the primary mechanisms involved in Par-4-induced 
apoptosis.  
Intracellular apoptosis by Par-4 
The extrinsic apoptotic pathway is utilized by Par-4 in hormone-independent 
cancers, wherein Fas/Fas ligand (Fas/FasL) are transported to the cell surface 
leading to the recruitment and activation of Caspase 8 via the death-inducing 
signaling complex (DISC) (Chakraborty et al., 2001). In conjunction with initiation 
of the caspase cascade, Par-4 is also translocated to the nucleus leading to the 
inhibition of NF-κB which is a key regulator of cell survival pathways. Normally, 
NF-κB mediates the transcription of a number of pro-survival genes like BCL-2, 
Bcl-xL among others; genes like X-linked inhibitor of apoptosis (XIAP) which are 
anti-apoptotic in nature and can inhibit TNF-induced apoptosis and provide a 
cyto-protective effect (Barkett and Gilmore, 1999; Nalca et al., 1999). The p65 
(Rel A) subunit translocates to the nucleus when activated by TNF. Par-4 has 
been shown to inhibit this process through the blockade of atypical protein kinase 
C (aPKC) thereby promoting apoptosis. Par-4 expression also inhibits the activity 
of inhibitory kappa B protein (IκB) kinase leading to its degradation. Since IκB 
10 
kinase is critical for NF-κB activation, this leads to Par-4-mediated inhibition of 
NF-κB in the cells (Diaz-Meco et al., 1999). As mentioned above, the nuclear 
translocation of Par-4 is essential for intracellular apoptosis by Par-4. This is 
brought about by the phosphorylation of a key threonine reside at the 155 
position (Thr155) by the enzyme Protein Kinase A (PKA). This phosphorylation 
event is crucial for the activity of Par-4 as it activates Par-4 which induces 
Fas/FasL translocation to the cell membrane as well as the inhibition of NF-κB. 
Unless the T155 residue is phosphorylated by PKA, Par-4 is unable to 
translocate to the nucleus; however, this event alone is insufficient to drive 
nuclear entry. The translocation into the nucleus thus relies on a combination of 
events, some of which are yet to be elucidated. Of note, the T155 
phosphorylation site lies within the SAC domain of Par-4, which also contains the 
NLS2 sequence. The PKA phosphorylation of Par-4 at this critical T155 residue 
also confers Par-4 its cancer selective trait to induce apoptosis. This attribute is 
largely due to the fact that most cancers show elevated PKA activity possibly due 
to higher metabolic demands of cancer cells to sustain a rapid rate of cell division 
(Gurumurthy et al., 2005). As normal cells do not express high levels of PKA, the 
phosphorylation of the T155 residue does not occur as efficiently, hence SAC or 
full length Par-4 is unable to induce apoptosis in normal cells. SAC transgenic 
mice which overexpress the green fluorescent protein (GFP) tagged SAC domain 
in all their tissues were found to be extremely resistant to the growth of both 
spontaneous as well as oncogene-induced tumors (Zhao et al., 2007). 
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Extracellular apoptosis by Par-4 
For many years Par-4 research focused on the intracellular apoptotic effects of 
Par-4 in cancer cells due to the assumption that Par-4 is an intracellular protein. 
However, a seminal paper by Burikhanov et al. in 2009, led to a paradigm shift in 
the understanding of Par-4 biology. The studies showed that Par-4 was actively 
secreted by the cells, and that this secreted Par-4 was completely functional and 
exhibited the same cancer selective apoptotic ability as intracellular Par-4. They 
showed that Par-4 was secreted by a wide array of normal cells, immortal cells 
and cancer cells. The secretion of Par-4 was induced significantly by factors that 
caused ER stress within the cells (Burikhanov et al., 2009). Under such 
conditions, glucose regulated protein 78 (GRP78, also known as immunoglobulin 
heavy-chain binding protein BiP), which is normally an ER resident chaperone 
protein that regulates protein folding and is believed to be a ‘master regulator’ of 
ER function, binds to Par-4. This GRP78-Par-4 complex is trafficked to the cell 
membrane under ER stress conditions (Kaufman, 1999; Lee, 2007). The 
secreted Par-4 is able to induce cancer selective apoptosis, due to the GRP78 at 
the cell surface acting as a membrane receptor for the SAC domain within Par-4. 
Binding of the SAC domain to cell surface GRP78, results in the recruitment of 
FADD to the cell surface, followed by initiation of the caspase cascade involving 
caspase 8 and caspase 3 activation and resulting in apoptosis. ER stress plays a 
pivotal role in the apoptosis by extracellular Par-4 as well translocation of GRP78 
from the ER to cell membrane. The PKR-like ER Kinase (PERK) is activated in 
repose to ER stress and has been shown to regulate FADD-caspase-8-
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dependent apoptosis (Park et al., 2008). The observation that phospho-PERK 
was highly induced in cells treated with recombinant Par-4 protein, and that the 
downregulation of PERK using RNAi  caused inhibition of the extrinsic apoptotic 
pathway led to the conclusion that  PERK is a likely factor that links ER stress to 
apoptosis by extracellular Par-4 (Burikhanov et al., 2009). 
Ubiquitin Proteasome System (UPS) 
Proteins are key molecules that form the structural and functional components of 
many cellular processes. Hence, maintaining the quality and integrity of the 
amino acid, sequence as well as tertiary structure of the protein is critical for 
normal cellular function. Errors in amino acid sequence or misfolding of proteins 
can lead to complete or partial loss of function and in some cases also have toxic 
effects on the cell. To prevent accumulation of misfolded proteins cells have a 
robust quality control mechanism in the form of the Ubiquitin Proteasome System 
(UPS). The primary role of the UPS is to facilitate the removal of misfolded 
proteins and prevent protein aggregation. The UPS has multiple components like 
the E1 enzymes responsible for ubiquitin activation, the ubiquitin conjugating E2 
enzymes and the E3 ubiquitin ligases. These enzymes work in succession to tag 
protein substrates with a polyubiquitin peptide that allows it to be recognized by 
the proteasome and leads to its subsequent degradation (Amm et al., 2014).   
Due to its significant role in the degradation of cytoplasmic and nuclear proteins 
the UPS has been extensively studied in the field of cancer biology. The E3 
ligases are often found to support tumorigenesis and progression of cancer by 
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facilitating the degradation of tumor suppressor proteins and cell cycle regulators. 
Mutations within certain E3 ligases in tumors prevent the degradation of cell 
survival factors, and thereby support cancer growth (Devoy et al., 2005). 
E3 Ligases 
E3 ligases form an important part of the UPS and play the crucial role of 
substrate recognition and ubiquitination. There are a variety of E3 ubiquitin 
ligases found within cells, with many of them displaying different mechanisms of 
action that may be dependent on the cellular localization of the E3 ligase or the 
nature of the substrate. Due to the diversity of protein substrates within cells, it is 
understandable that E3 ligases responsible for the clearance of these proteins 
are similarly varied. In the past decade or more findings that E3 ligases are often 
mutated or dysfunctional in different diseases such as cancer and 
neurodegenerative disease has sparked significant interest in therapeutic 
targeting of these enzymes (Devoy et al., 2005; Shimura et al., 2000; Sun, 2003). 
The E3 ligases can be broadly classified into 3 distinct types, HECT (homologous 
to E6-associated protein C-terminus), U-box E3 ligases, RING finger E3 ligases 
HECT (homologous to E6-associated protein C-terminus) domain E3 ligases 
were the earliest identified and are characterized by a 350 amino acid catalytic 
domain. The N-terminal region of the HECT domain is involved in substrate 
recognition and binding while the role of critical cysteine residues located 
centrally in the HECT domain is similar to the E2 ligases that accept ubiquitin; the 
C-terminal region of the HECT domain is responsible for its E3 ligase activity of 
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transferring the ubiquitin to the substrate. Unlike the following two classes the 
HECT domain E3 ligases play a catalytic role in ubiquitination. 
U-box E3 ligases are 74 amino acids long. Although they have some similarities 
to the RING finger domain, U-box ligases use salt bridges to maintain structural 
integrity as they do not possess the residues that are essential for metal 
chelation. Due to the structural similarities between U-box and RING finger 
domain E3 ligases the U-box E3 ligases often act like the RING E3 ligases where 
they may function independently or in complexes with other proteins. The most 
widely studied U-box proteins CHIP is a co-chaperone that is involved in the 
regulation of protein folding by the respective chaperones and functions in quality 
control through UPS-mediated degradation. The N-terminal domain of CHIP 
interacts with Hsp70 and Hsp90 which control its substrate specificity. CHIP has 
a variety substrates, some of which play important roles in neurodegenerative 
diseases like the Tau protein linked to Alzheimer’s or the cystic fibrosis 
transmembrane conductance regulator (Ardley and Robinson, 2005).  
RING finger E3 ligases form the largest subgroup of the E3 ligases. There are 
two defined subclasses within the RING finger E3 ligases, RIR (RING in between 
RING–RING) domain, and multi-protein complex E3 ligases [CRL (Cullin-RING 
E3)]. The RING finger E3 ligases lack the catalytic activity of HECT domain E3 
but instead act as scaffolding proteins that allow other proteins and E2 enzymes 
to interact with substrates. The RING finger domain is a zinc-chelating domain 
which is rich in cysteines/histidine residues and it allows for protein-protein as 
well as DNA-protein interactions. The RING finger E3 ligases play important roles 
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in cancer biology, the most notable being MDM2, which is responsible for 
degradation of the tumor suppressor p53. Increased levels of p53 induce 
apoptosis, hence, in normal cells p53 is maintained at low levels due to a tight 
control exerted by MDM2. When p53 levels increase in the cell, it acts as a 
transcriptional activator of MDM2 gene expression, following which MDM2 binds 
to p53 and ubiquitinates it, thereby mediating its degradation by the 26S 
proteasome.  
Among the 7 classes of cullin-based E3 ligases, the Skp1-Cul1-F-box-protein 
(SCF) complex forms a large and important group that is found to play a role in 
cancer and neuronal diseases. The SCF complex E3 ligases are made of the 
scaffold protein Cul1, Rbx1/Roc1 which is a RING-domain protein, Skp1 that acts 
as an adaptor protein, and an F-box protein. The F-box proteins, of which there 
are several, provide substrate binding sites and confer substrate specificity. The 
N-terminal F-box motif allows the F-box proteins to interact with Skp1 while a C-
terminal protein-protein interaction domain provides sites for substrate 
recognition and binding.  Due to the diversity in the number of F-box proteins, a 
number of target proteins have been discovered. β-catenin, IκBα and cyclin 
dependent kinase inhibitors like p27Kip1, p21Cip1 are some examples of 
proteins that are recognized by F-box proteins and targeted for degradation by 
the UPS. One such E3 ligase which has been reported to play an important role 
in neuronal diseases and cancer is Fbxo45. 
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Fbxo45 
Fbxo45 encoded by the Fbxo45 gene is an F-box E3 ubiquitin ligase that is 
highly conserved across various species from C. elegans to mammals. Fbxo45 
was first identified and characterized as an estrogen induced gene containing 3 
exons. The transcriptional start site was shown to contain several consensus 
binding sites for the estrogen receptor and a significant increase in Fbxo45 
transcription was observed in response to 17β-estradiol (Yoshida, 2005). In 
2009, Saiga et al. demonstrated that as opposed to other SCF E3 ligases, 
Fbxo45 did not form an SCF complex. The consensus binding site for the F-box 
domain in Fbxo45 contains a substitution of the critical amino acid residues 
required for binding to Cul1 and Rbx1; as a result it is unable to bind to Cul1 or 
Rbx1 preventing SCF complex formation. Using an Fbxo45 knock out mouse 
they showed that it is required for essential processes of neural development like 
neuronal migration, axonal projection and synapse formation (Saiga et al., 2009). 
Subsequently Fbxo45 was also shown in the nervous system as a critical 
regulator of synaptic activity in the hippocampal neurons. It was classified as 
ubiquitin ligase, and was found to be involved in the degradation of the synaptic 
vesicle priming factor Munc-13-1. The SPRY protein interaction domain found at 
the C-terminal region of Fbxo45, was responsible for its ability to recognize and 
interact with Munc13-1 and target it for degradation (Tada et al., 2010). Fbxo45 
has also been implicated in cancer cell survival and conferring apoptosis 
resistance by binding and ubiquitinating pro-apoptotic proteins like p73 and Par-
4, resulting in their proteasome mediated degradation. P73, a transcription factor 
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belonging to the p53 family, is maintained at low levels within the cells by 
ubiquitination by the E3 ligases Itch and Fbxo45. In response to DNA damage in 
the cell, p73 levels are upregulated which is combined with downregulation of 
Itch and Fbxo45 (Peschiaroli et al., 2009). The role of Fbxo45 in promoting 
cancer cell survival became even clearer when it was found to interact with the 
tumor suppressor protein Par-4 and mediate its proteasomal degradation. Using 
deletion mutants the study showed that the F-box domain in Fbxo45 is 
responsible for its binding with the RING finger protein PAM (protein-associated 
with myc) and Skp, whereas the SPRY domain is critical for Fbxo45 to recognize 
and directly bind Par-4. Fbxo45 forms an atypical ligase complex that binds Par-4 
and degrades it (Chen et al., 2014).  
SPRY domain 
The SPRY domain is an evolutionarily ancient domain that is conserved across 
fungi, plants and animals. It is found in over 150 proteins spanning 11 protein 
families. Some of these families include the SSB (SPRY domain containing 
SOCS Box) protein family that has diverse roles depending on its association 
with other proteins. The SPRY domain is centrally located in the SSB proteins 
which have a C-terminal SOCS box domain that allows them to interact with 
Elongin C resulting in the formation of a multiprotein ubiquitin ligase complex. 
The tripartite/RBCC motif (TRIM) family of proteins is another important group, as 
point mutations within the SPRY domain of proteins like MID1 (E3 Ubiquitin 
ligase activity) cause inherited diseases. The SPRY domain containing protein 
families are also involved in other important physiological and cellular processes. 
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To name a few, DDX1, hnRNPs are involved in RNA metabolism, while the 
ryanodine RyR receptors mediate intracellular calcium release (Rhodes et al., 
2005). 
In the context of Par-4, a short sequence motif binds to the SPRY domain within 
the SSB protein SSB-1. Valuable information was obtained during the crystal 
structure determination of the SPRY domain for the only drosophila SSB protein, 
GUSTAVUS. In a complex with the 20 amino acid VASA (a DEAD-box RNA 
helicase) peptide, it was revealed that site of peptide binding has a rigid 
conformation and a preformed binding pocket. This preformed pocket in 
GUSTAVUS is crucial for ensuring the high affinity binding with a short segment 
(Asp184-Ile185-Asn186-Asn187-Asn188-Asn189; denoted as D-I-N-N-N-N) 
within the VASA peptide. Using a series of substitution mutations it was 
concluded that the pocket binds tightly to a six amino acid sequence D-I-N-N-N-X 
where X can be any amino acid. Incidentally, the F-box proteins containing the 
SPRY domain and three proteins belonging to the human SSB protein family 
have the same conserved peptide-binding residues observed in GUSTAVUS. 
The short sequence motif ELNNNL within Par-4 was identified as the binding site 
for SSB-1 based on the above observations (Woo et al., 2006).  
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Figure 1.1: Pathways of Apoptosis 
From Fesik, S.W., Nature Reviews Cancer. Nov 2005; 5, 876-885 
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Figure 1.2: Diagram of the critical domains of Par-4 
The nuclear localization sequences NLS1 and NLS2, SAC domain and leucine 
zipper domain are conserved across human, rat and mouse. The site for PKA 
phosphorylation within the SAC domain that activates Par-4 to induce apoptosis 
is also present in all three species. 
From Hebbar et al. J Cell Physiol. 2012 Dec; 227(12):3715-21 
21 
Figure 1.3: Apoptosis by Par-4 
Par-4 induces apoptosis by acting intra-cellularly and extra-cellularly in cancer 
cells. Par-4 activates the extrinsic apoptotic, FADD-caspase 8 pathway, and is 
transclocated to the nucleus to inhibit TOPO I and NF-κB dependent 
transcription. Par-4 translocates GRP78 to the cell surface under ER stress and it 
gets secreted. The SAC domain in secreted Par-4 then binds to GRP78 at the 
plasma membrane to signal caspase activation and induce apoptosis in a cancer 
cell specific manner. 
From Hebbar et al. Anticancer Genes, 2014; Advances in Experimental Medicine 
and Biology 818 
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Figure 1.4: Ubiquitin transfer mechanisms. The transfer of Ubiquitin from 
enzymes E1 to E2 occurs through a transthiolation step. The protein substrate 
(S) is then ubiquitinated by the E3 ligase (A) HECT domain E3 ligases catalyze 
the transfer of Ubiquitin onto the substrate (B) RING finger and U-box E ligases 
do not have the ability to catalyze the transfer hence need additional protein 
complexes or and E2 ligase to ubiquitinate the substrate. One the substrate has 
been polyubiquitinated it is recognized by the 26S proteasome and degraded. 
From Ardley, H.C. and Robinson, P.A. Essays In Biochemistry, 2005, 41 15-30 
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Figure 1.5: The VASA-like sequence motif in Par-4. Par-4 contains a short 
sequence ELNNNL which is a VASA-like motif, located between residues 68-73 
(highlighted in green). This VASA-like motif in Par-4 is found within the amino 
acids 1-131. The DINNNN sequence in the VASA peptide is shown in alignment 
with the ELNNNL motif in WT Par-4 and the mutant N72A Par-4. The N72A 
mutant does not bind to SPRY domain in SSB-1 highlighting the significance of 
sequence conservation in the motif.  
Adapted from Woo et al. Mol Cell. 2006 Dec 28;24(6):967-76. 
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Figure 1.6: Fbxo45 targets Par-4 for degradation. Fbxo45 belongs to the 
Cullin subtype of RING finger domain E3 ligases. It contains ad SPRY domain 
that recognizes a VASA domain like sequence (ELNNNL) within the tumor 
suppressor Par-4. Fbxo45 binds to Par-4 and ubiquitinates it in the cytoplasm 
and targets it for proteasomal degradation. 
Adapted from Wang, Z and Wei, W. Cell Death Differ. 2014; 21: 1508–1510. 
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Project objectives 
Previous studies from our laboratory and multiple other laboratories around the 
world have focused on the SAC domain of Par-4 as the killer domain that confers 
Par-4 with the potential to induce cancer specific apoptosis. In this dissertation 
my aim is to identify a novel factor that is released from cancer cells that are 
undergoing apoptosis in response to treatment, and that is capable of inducing 
apoptosis in the surrounding therapy resistant cell populations. This hypothesis 
uses the concept of tumor heterogeneity and exploits the potential of therapy in 
the therapy sensitive cells within a tumor. The significance of this hypothesis is 
that most tumors are heterogeneous and exhibit the presence of sensitive and 
resistant cells within a single tumor. 
Chapter 2: PAF induced apoptosis in therapy resistant tumors. 
1. To determine whether tumor heterogeneity provides a therapeutic
advantage in treatment of solid tumors.
2. To identify factor/s released from therapy sensitive cells in response to
treatment and study their effect on therapy resistant cells
3. To study the mechanism of action of  the released factor/s
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CHAPTER TWO: PAF INDUCES APOPTOSIS IN THERAPY RESISTANT TUMORS 
INTRODUCTION 
Par-4 induces apoptosis specifically in cancer cells but not in normal cells by 
intracellular and extracellular mechanisms. Basal levels of Par-4 are inadequate 
by themselves to induce apoptosis of cancer cells, yet can sensitize cells to the 
action of various apoptotic insults (Burikhanov et al., 2014). Par-4-knockout mice 
develop spontaneous, as well as inducible tumors (Garcia-Cao et al., 2005); in 
contrast, transgenic mice overexpressing Par-4 are resistant to the growth of 
spontaneous or oncogene-inducible tumors (Zhao et al., 2007). Consistent with 
its tumor suppressor function, a number of laboratories have reported that Par-4 
is inactivated, down-regulated, or mutated in different types of cancers (Boehrer 
et al., 2001; Cook et al., 1999; Johnstone et al., 1998; Kogel et al., 2001; 
Moreno-Bueno et al., 2007) 
Par-4 protein has been localized to various cellular compartments, and Par-4 
exerts its intracellular apoptotic function in the cytoplasm and/or in the nucleus by 
interacting with diverse proteins via its leucine zipper domain or via its centrally 
situated SAC domain. Moreover, Par-4 that is localized to the endoplasmic 
reticulum (ER) is secreted constitutively and is also inducible in response to 
various ER-stress producing agents or small molecule secretagogues. Elevation 
of extracellular Par-4 in cell culture conditioned medium (CM) or systemically in 
mice induces apoptosis specifically in cancer cells leading to growth inhibition of 
tumors (Zhao et al., 2011). Secreted Par-4 binds, via the SAC domain, to its 
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receptor GRP78 on the surface of cancer cells and induces apoptosis by a 
FADD/caspase-8/caspase-3 dependent pathway (Burikhanov et al., 2009). 
Normal cells, on the other hand, are resistant to apoptosis by extracellular Par-4 
as they express low to undetectable levels of basal or inducible cell surface 
GRP78 receptors (Burikhanov et al., 2009).  
Apoptosis induced by secreted Par-4 is dependent on cell surface receptor 
GRP78 and intracellular Par-4 function, and diverse tumor cells exhibit resistance 
to Par-4 either by inactivation or downregulation of intracellular Par-4 activity or 
downregulation of cell surface GRP78. These tumor cells may be also resistant 
to the action of cancer therapeutics. Several reports have indicated that cells 
undergoing apoptosis can release factors that induce paracrine apoptosis of 
neighboring cells in the microenvironment. However, the precise factor(s) have 
never been identified. We tested the hypothesis that treatment of therapy-
sensitive cancer cells with apoptosis-inducing therapeutics may induce paracrine 
apoptosis in neighboring therapy-resistant cancer cells grown in heterogeneous 
microenvironments. Rather unexpectedly, we identified a novel N-terminal 
fragment of Par-4, PAF that is released from therapy-sensitive cancer cells 
following caspase-dependent cleavage of Par-4. This therapy-generated 
fragment induces apoptosis specifically in cancer cells, including those that are 
resistant to therapy, as well as to the action of Par-4.  
The mechanism for apoptosis by PAF is independent of cell surface GRP78, thus 
differentiating it from Par-4/SAC mediated apoptosis. However, the ability of PAF 
to induce apoptosis is dependent on the presence of intracellular Par-4. PAF 
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induces apoptosis by preventing the degradation of intracellular Par-4 by SPRY 
domain containing ubiquitin ligases such as Fbxo45 which bind to its VASA 
domain (Chen et al., 2014). 
MATERIALS AND METHODS 
Cells, plasmids, and chemical reagents 
Human prostate cancer cells DU145, PC-3, LNCaP, lung cancer cells A549 and 
H460, primary human lung fibroblast cells HEL and epithelial cells Beas-2B were 
from ATCC, MD. Mel1617 and Mel1617BR melanoma cells were from Meenhard 
Herlyn (Wistar Institute, PA). The LNCaP-derivative C4-2B cells were from 
Leland Chung (Ceder Sinai Medical Center, LA), normal human prostate stromal 
cells PrS and prostate epithelial cells PrE were from Lonza Inc. (Allendale, NJ).  
KP7B cells were from Tyler Jacks (MIT, MA). Par-4+/+ (wild type) and Par-4-/- 
mouse embryonic fibroblasts (MEFs) were obtained from wild type and Par-4-null 
C57BL/6 mice. Beas2B and Arsenic-transformed Beas2B cells were from 
Xianglin Shi (University of Kentucky). Parent A549 and A549TR cells were from 
Bruce Zetter (Boston Children’s Hospital, MA).  Paclitaxel injection vials were 
obtained from the Markey Cancer Center pharmacy for research use only. Z-
VAD-fmk, z-DEVD, z-IETD-fmk, z-LEHD-fmk were from BioVision Inc. 
Recombinant human TRAIL was from Calbiochem. BFA was procured from 
Sigma. PLX-4720 was from Plexxicon Inc., CA. The Par-4/3A mutant was a gift 
from Kojo S. Elenitoba-Johnson (University of Michigan). The shRNA for Par-4 
was constructed using the pLKO.1 vector and a stable cell line was generated by 
Dr. Sunil Noothi in our laboratory. Purified recombinant thioredoxin (TRX), TRX 
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Par-4 and TRX-PAF were procured from ProMab Biotechnologies Inc. Purified 
Par-4-His and PAF-His was prepared using the baculoviral protein expression 
system by GenScript, NJ. 
siRNA duplexes and transfection 
Plasmids for expression of GFP, non GFP vector pCB6+, pCB6+ Par-4, pCB6+
132-340, Par-4 GFP, pcDNA3.1-nV5 Par-4/3A mutant have been described 
previously  (Chen et al., 2014; El-Guendy et al., 2003). The expression constructs 
for PAF and PAF3A mutant were cloned into the pCB6+ vector backbone 
following PCR amplification of the cDNA for amino acids 1-131 using pCB6+ Par-
4 or pcDNA3.1-nV5 Par4-3A constructs respectively, as templates. The pCB6+
vector was cut using the restriction enzyme EcoR1, and the cDNA was then 
ligated into the vector. Fidelity of the sequence was confirmed by nucleotide 
sequencing. The control siRNA and pools of siRNA for Par-4 were from 
Dharmacon and SantaCruz Biotechnology, Inc. respectively  
Co-immunoprecipitation and Western blot analysis 
Cells were lysed using RIPA (Radio Immuno Precipitation Assay) buffer and 
Complete Protease Inhibitor cocktail (Roche) on ice. The lysates were 
centrifuged at 13000 rpm for 5 minutes at 4°C and the supernantant was used for 
the pulldown. The protein concentration was determined by Bradford assay using 
a cuvette based spectrophotometer. The proteins were immunoprecipitated using 
1 mg of input and 2 µg antibody and 25 µl bed volume of magnetic protein A/G 
beads from ThermoFisher Scientific. The proteins were then eluted and resolved 
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using SDS-PAGE. The Western blot analysis was carried out as described 
previously (Goswami et al., 2008).  
Antibodies  
Par-4 (R332), Col1A1 (H-197), anti-His, Fbxo45 and Rabbit IgG antibodies were 
from Santa Cruz Biotechnology, Inc. The C-terminal Par-4 mouse monoclonal 
antibody and that for β-actin was from Sigma Chemical Corp.  
Apoptosis assays 
The cells were seeded in 8 well chamber slides and treated/transfected with 
respective agents. Following completed of treatment the cells were fixed using 
10% Neutral Buffered Formalin and the washed with PBS. The slides were 
mounted with coverslips using Vectashield mounting medium with 4, 6-diamidino-
2-phenylindole DAPI (Vector Biolabs) and incubated overnight at 4°C. Apoptotic 
nuclei were identified by pyknosis or nuclear fragmentation. A total of three 
independent experiments were performed; and approximately 500 cells were 
scored in each experiment for apoptosis with fluorescence microscopy. 
Immunocytochemistry was performed by fixing cells on the slide followed by 
primary antibody incubation. The secondary antibody was a conjugated Alexa 
Fluor 488 (green fluorescence) or Alexa Fluor 594 (red fluorescence). The 
stained cells were imaged using a confocal or a fluorescence microscope. 
Animal experiments 
A549 xenograft model: Nude mice were obtained from Jackson Laboratories at 
3-4 weeks of age. The animals were injected s.c. with 2x106 cells of either A549 
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or A549TRGFP cells into both flanks. In the group with mixed tumors, 1x106 cells 
of each cell type (A549 and A549TR/GFP) were mixed and injected s.c. in mice. 
Following tumor formation, the animals were treated with paclitaxel (12 mg/kg) or 
injectable saline as vehicle control. The tumors were measured using Vernier 
calipers every 3 days for period of 28 days. Following treatment the tumors were 
excised and subjected to TUNEL staining to evaluate apoptosis. The TUNEL kit 
was obtained from EMD Millipore. TUNEL staining was carried out at the Markey 
Cancer Center Biospecimen Shared Resource facility. 
LLC-1 experimental metastasis model: Lewis Lung Carcinoma (LLC-1) cells were 
injected into mice through the tail vein. The animals received i.v. injections of 
His-PAF (250 µg) or vehicle . The first i.v. injection of His-PAF protein was given 
5 hours after the LLC-1 cells were injected. The tumors were allowed to 
develop for a period of 18 days. The animals were humanely killed and the 
lungs were stained with India ink. The tumors nodules were counted with the 
aid of a dissection microscope. 
 All animal procedures were performed with IACUC approval. 
Statistical analysis 
All experiments were performed in triplicate to verify the reproducibility of the 
findings. Statistical analyses were carried out with Graphpad Prism or Microsoft 
Excel software, and p- values were calculated using the Student t test unless 
otherwise mentioned. 
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RESULTS 
Tumor cell heterogeneity permits cancer therapeutics to overcome therapy 
resistance 
Paclitaxel is a microtubule inhibitor representing the taxane family of drugs, and 
is commonly used as a standard of care therapy for a broad range of cancers. To 
test the effect of paclitaxel on taxane-resistant cancer cells grown within the 
microenvironment of taxane-sensitive cancer cells, we treated co-cultures of 
RFP-tagged Paclitaxel-sensitive A549 lung cancer cells and GFP-tagged 
paclitaxel-resistant A549TR cells with paclitaxel. As seen in Figure 2.1A, 
paclitaxel treatment (25 nM) of the co-cultures resulted in apoptosis of the 
A549/RFP cells, as well as the A549TR/GFP cells. On the other hand, when 
grown separately, the A549 cells were susceptible to paclitaxel (25 nM) induced 
apoptosis but the A549TR cells were resistant to paclitaxel (25 nM). We then 
examined the conditioned medium (CM) from paclitaxel-treated A549/RFP cells 
or A549TR/GFP cells for apoptosis in A549TR/GFP target cells. The CM from 
paclitaxel-treated A549/RFP cells but not from paclitaxel-treated A549TR/GFP 
cells induced apoptosis in A549TR/GFP (Figure 2.1B).   
To determine the in vivo significance of these observations in a heterogeneous 
tumor microenvironment, we injected a 1:1 mixture of A549 and A549TR/GFP 
cells into the flanks of immunocompromised nude (nu/nu) mice. As control, mice 
were injected with either A549 cells or A549TR/GFP cells. After the tumors 
attained a size of 4-mm, the mice were treated with paclitaxel or vehicle, and the 
growth of the tumors was monitored over a 28 day period. Interestingly, paclitaxel 
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treatment caused a remarkable inhibition of mixed tumor-cell xenografts 
containing A549 and A549TR/GFP cells (Figure 2.1C).  By contrast, xenografts 
of A549TR/GFP cells injected separately in different mice were resistant to 
paclitaxel (Figure 2.1C). Moreover, TUNEL assays confirmed significant 
apoptosis in the A549TR/GFP cells from the tumors arising from injection of 
A549 and A549TR cells, relative to the A549TR/GFP cells in the tumors arising 
exclusively from A549TR/GFP injections (Figure 2.1C). Together, these findings 
indicate an abscopal effect produced by a soluble factor secreted by paclitaxel-
sensitive lung cancer cells that induces paracrine apoptosis in paclitaxel-resistant 
lung cancer cells.  
We next performed an unbiased screen of potential proteins that are secreted 
from A549 cells that may induce apoptosis in paclitaxel-resistant lung cancer 
cells. A549 cells were treated with paclitaxel and the CM was applied to the 
A549TR cells. The CM was incubated with antibodies against potential candidate 
proteins, such as TRAIL, GDF15, Maspin, IGFBP3, or Par-4 that are known to be 
secreted and induce apoptosis. Rather surprisingly, although both A549 and 
A549TR cells are resistant to Par-4, the Par-4 antibody caused ~70% decrease 
in apoptosis by the CM, relative to the control IgG (Figure 2.1D). By contrast, the 
Maspin antibody caused ~30% decrease in apoptosis by the CM and antibodies 
for TRAIL, IGFBP3, GDF15 did not inhibit apoptosis by the CM (Figure 2.1D). 
These findings implicated a Par-4-like factor in paracrine apoptosis of paclitaxel-
resistant A549TR cells. 
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Identification of the Par-4-like candidate factor involved in paracrine 
apoptosis of diverse therapy-resistant cancer cells 
To identify the Par-4-like secreted factor that produced apoptosis in therapy-
resistant cells, we treated A549 lung cancer cells with paclitaxel and applied the 
CM to A549TR cells in the presence of a control IgG antibody, a Par-4 polyclonal 
antibody that preferentially recognized the N-terminal of Par-4 (N-terminal 
antibody), or a C-terminal antibody that detects a 20 aa sequence at the C-
terminus of Par-4 (C-terminal antibody). Interestingly, apoptosis by the CM was 
neutralized by the N-terminal antibody but not by the C-terminal antibody or the 
control antibody (Figure 2.2A). Western blot analysis of the CM with the Par-4 
antibodies resolved 3 distinct bands- (1) full-length Par-4 at ~40 kDa, which was 
detected by both the N- and C-terminal Par-4 antibodies, (2) a 25 kDa band, 
which was detected by the C-terminal antibody, and (3) a 15 kDa band, which 
was detected by the N-terminal antibody (as seen in Figure 2.2E). Because the 
N-terminal antibody, which neutralized the apoptotic action of the CM, detected 
full length Par-4 and the 15 kDa band, and because A549 cells and A549TR cells 
were resistant to the action of full-length Par-4 (Burikhanov et al., 2013; 
Burikhanov et al., 2009), the 15 kDa band was a prime candidate for the 
paracrine apoptotic action of paclitaxel in A549TR cells.  
We further validated this concept using diverse therapy-resistant cell culture 
models, such as prostate cancer cells DU145 that are resistant to the TNF-
related apoptosis inducing ligand (TRAIL) or the anti-androgen bicalutamide, or 
melanoma cells that are resistant to the BRAF-inhibitor PLX-4720. TRAIL-
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sensitive PC-3 cells were treated with TRAIL, and the CM was applied to TRAIL-
resistant DU145 cells (Figure 2.2B). Similarly, LNCaP cells, which are sensitive 
to bicalutamide, were treated with bicalutamide and the CM was applied to the 
bicalutamide-resistant DU145 cells (Figure 2.2C). We also treated melanoma 
cells Mel1617, which are sensitive to the BRAF inhibitor PLX-4720, and the CM 
was applied to Mel1617BR melanoma cells which are resistant to PLX-4720 
(Figure 2.2D). Interestingly, the CM from the TRAIL, bicalutamide, or PLX-4720-
treated therapy-sensitive cancer cells produced apoptosis in the corresponding 
therapy-resistant cells (Figures 2.2B, 2.2C, 2.2D). Importantly, the apoptotic 
activity in the CM from the TRAIL- or bicalutamide-treated therapy-sensitive 
cancer cells was neutralized by the N-terminal Par-4 antibody but not the C-
terminal Par-4 antibody, and the 15 kDa band was present in each of the CM 
tested (Figures 2.2B and 2.2C). The 15 kDa band was also present in the CM 
from the PLX-4720 treated therapy-sensitive cancer cells, and the apoptotic 
activity of the CM was neutralized by the N-terminal Par-4 antibody, as well as by 
the C-terminal Par-4 antibody (Figures 2.2D). Moreover, doxorubicin, which is 
used for treatment of a wide range of cancers, induced apoptosis in lung cancer 
cells H460 and produced the 15 kDa band (Figure 2.2E). These findings 
suggested that the 15 kDa band represented a candidate factor released by 
therapy-sensitive cells that may effectively induce apoptosis in therapy-resistant 
tumor cells. 
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Identification of PAF 
Since TRAIL, paclitaxel, bicalutamide or PLX-4720 induces apoptosis through 
the activation of intracellular caspases (Lee et al., 2003; Schneider et al., 1997; 
Tsai et al., 2008; Weigel et al., 2000) we considered the possibility that the 15 
kDa and 25 kDa bands represented N- and C-terminal caspase-cleavage 
fragments, respectively, of Par-4. An in silico search of caspase cleavage sites 
within Par-4 identified a potential cleavage site at the D131 position 
(D131EEEPD). Moreover, pretreatment of H460 cells with TRAIL in the presence 
of cycloheximide, which is known to inhibit de novo protein biosynthesis, did not 
inhibit production of the 25 kDa and 15 kDa bands (Figure 2.3A, left panel), 
indicating that production of these fragments was not dependent on new gene 
expression events. We also transfected H460 cells with Par-4-tagged with GFP 
at the C-terminus (Par-4-CT-GFP), which is known to activate caspase-
dependent apoptosis (Chakraborty et al., 2001) Despite fusion of GFP at the C-
terminus, Par-4-CT-GFP produced the 15 kDa band, indicating that the 15 kDa 
fragment was not a result of alternate splicing or antibody cross-reaction with 
other proteins (Figure 2.3A, right panel). On the other hand, pretreatment of cells 
with the pan-caspase inhibitor z-VAD-fmk inhibited the generation of the 25 kDa 
and 15 kDa fragments indicating that these fragments were produced by 
caspase-dependent cleavage of Par-4 (Figure 2.3B, left panel). To further 
confirm these findings, we made a site specific D131A mutant of Par-4, which 
was expected to be resistant to caspase activity. As expected, ectopic 
expression of full length Par-4, which produces apoptosis in H460 cells, 
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produced the 25 kDa and 15 kDa fragments, and the products of the 1-131aa or 
132-340aa deletion mutant constructs of Par-4 co-migrated with the 15 kDa or 25 
kDa band, respectively (Figure 3A). By contrast, overexpression of the D131A 
mutant of Par-4 failed to produce the Par-4 cleavage fragments (Figure 2.3B, 
right panel). Moreover, TRAIL, which activates caspase 3, further enhanced the 
production of the 25 kDa and 15 kDa bands in TRAIL-sensitive cells transfected 
with the Par-4 expression construct but not with the D131A mutant of Par-4, 
relative to vector (Figure 2.3C). H460 cells treated with TRAIL showed a linear 
increase in the amount of the 15 kDa cleavage fragment with time (Figure 2.3D), 
indicating an augmentation of Par-4 cleavage with increasing active caspase 
concentration within the cells.  Together, these findings indicated that the 15 kDa 
band was produced by caspase cleavage of Par-4 and that the D131 residue 
was critical for caspase induced cleavage of Par-4. We designated this 1-
131aa/15 kDa, fragment as PAF (Par-4 Amino-terminal Fragment). 
PAF induces apoptosis selectively in cancer cells 
To investigate whether PAF induces apoptosis, we transfected 3T3 fibroblasts 
with vector, human Par-4 or PAF expression constructs, and the CM from the 
transfected cells was transferred to diverse normal or cancer cell lines. The CM 
from PAF transfected cells induced apoptosis in diverse cancer types, regardless 
of whether they were sensitive or resistant to apoptosis by the CM from Par-4 
transfected cells, but did not induce apoptosis in normal cells (Figure 2.4A). To 
confirm our findings of the cancer-specific apoptotic potential of PAF, we used 
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recombinant PAF. As seen in Figure 2.4B, recombinant PAF induced apoptosis 
in Par-4-resistant cancer cells, as well as Par-4-sensitive cancer cells, but not in 
normal cells. Together, these findings indicate that PAF induces apoptosis 
specifically in cancer cells including those that are resistant to apoptosis by 
exogenous full length Par-4. 
Mechanism of PAF induced apoptosis 
As Par-4 induces apoptosis via the caspase 8/caspase 3-dependent pathway, we 
sought to determine whether PAF utilized a similar or distinct apoptotic 
mechanism. To determine the involvement of caspase 8 and caspase 3 in the 
action of PAF, we transfected MEFs with vector, Par-4 or PAF expression 
constructs, and the CM from these transfected cells was applied to A549 cells in 
combination with the pan-caspase inhibitor z-VAD-fmk, caspase-8 inhibitor z-
IETD-fmk, caspase-3 inhibitor z-DEVD-fmk and caspase-9 inhibitor z-LEHD-fmk. 
Apoptosis by PAF was inhibited by the pan-caspase inhibitor, as well as by the 
caspase 8- and caspase 3- inhibitors, and relatively weakly inhibited by the 
caspase 9 inhibitor, which inhibits the mitochondrial apoptotic pathway (Figure 
2.5A).  
The caspase 8/caspase 3 pathway requires functional Fas-Associated Death 
Domain (FADD), which is critical for caspase-8 activation, and caspase 8, which 
is essential for the direct activation of effector caspase 3 and in certain cell lines 
for the direct activation of the mitochondrial/caspase 9 pathway through cleavage 
of t-BID (Li et al., 1998). To confirm the requirement of the caspase 8/caspase 3 
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pathway in the action of PAF, we treated prostate cancer cells PC-3, or PC-3 
cells expressing dominant negative FADD (to block FADD activation) or FLIP 
(FLICE Like Inhibitory Protein responsible for inhibiting caspase-8 activation) 
along with recombinant PAF or Par-4 proteins, or with TRX control protein. As 
seen in Figure 2.5B, similar to recombinant Par-4, recombinant PAF induced 
apoptosis in the PC-3 cells with an intact extrinsic apoptotic pathway but not in 
the PC-3 cells expressing dominant negative FADD or FLIP. These findings 
indicate that the FADD/caspase 8/caspase 3 pathway is essential for apoptosis 
by PAF. Collectively, our results suggest that PAF preferentially utilizes the 
FADD/caspase 8/caspase 3 and weakly utilizes the caspase 9/caspase 3 
pathway for induction of apoptosis in cancer cells.    
Previous studies indicated that the function of intracellular Par-4 in target cells is 
essential for the paracrine apoptotic activity of secreted Par-4. To investigate 
whether intracellular Par-4 was required for the paracrine effect of PAF, we 
silenced intracellular Par-4 expression in cancer cells by RNAi. Cells were either 
transfected transiently with Par-4 siRNA duplexes or stably transfected with Par-
4 shRNA to knock down Par-4 expression. The transfectants were then treated 
with recombinant Par-4, PAF or TRX protein. PAF induced significantly higher 
apoptosis relative to the vector control in the transfectants that expressed 
knockdown levels of Par-4, and the presence of intracellular Par-4 further 
enhanced the efficacy of PAF (Figure 2.5C, Figure 2.5D). These findings 
indicated that PAF induces apoptosis in a Par-4-dependent manner. To identify 
the domains of PAF that are critical for this apoptosis in cancer cells, we 
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generated deletion mutants of PAF. Wild type MEFs were transfected with these 
mutants and the CM was applied to the A549 and PC-3 cells. Apoptosis assays 
with the CM from the transfectants indicated that the most active region of PAF 
was localized between amino acids 60 and 90 (Figure 2.5E). These findings 
indicated that the 60-90aa domain of PAF was sufficient for induction of 
apoptosis in cancer cells. 
PAF sequesters Fbxo45 and prevents Par-4 degradation 
A screen for molecular signatures of potentially functional domains within the 60-
90aa residues of PAF revealed a VASA segment (ELNNNL) that is important for 
Par-4-binding to the SPRY domain of the E3 ubiquitin ligases, Fbxo45, SPSB1, 
SPSB2, and SPSB4. Our recent studies indicated that Fbxo45 causes rapid 
degradation of Par-4 by binding to the VASA segment. We therefore determined 
whether the VASA segment within PAF was essential for apoptosis of cancer 
cells. H460 cells were transfected with expression constructs for Par-4, Par-4 
with an ALANAL mutation introduced within its VASA segment, and vector for 
control. CM from the transfectants was transferred to A549 and A549TR lung 
cancer cells, PC-3 prostate cancer cells, and the Mel1617BR melanoma cells; 
the cells were scored for apoptosis. The CM from Par-4 transfectants but not 
from Par-4-ALANA mutant transfectants induced apoptosis in A549 and A549TR 
cells (Figure 2.6A, right panel). As expected, PC-3 cells and also the Mel1617BR 
underwent apoptosis with the CM from Par-4 or Par-4-ALANAL transfectants 
(Figure 2.6A, right panel), Western blot analysis of the CM from the H460 
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transfectants confirmed cleavage of both wild type Par-4 and Par-4/ALANAL 
mutant to generate the 15 kDa PAF fragment or PAF-mutant fragment, 
respectively (Figure 2.6A, left panel). 
Par-4 null MEFs were transfected with expression constructs for Par-4, PAF, 
mutant Par-4 (ALANAL) and mutant PAF (ALANAL), and then the CM from these 
cells was applied to the A549 cells with knockdown levels of Par-4. As observed 
in Figure 2.6B, cells with knockdown levels of Par-4 showed apoptosis in 
response to PAF, but mutant PAF failed to induce apoptosis in these cells. These 
data confirm that pro-apoptotic activity of PAF was dependent on the VASA 
segment. 
To determine whether the VASA segment was sufficient to induce apoptosis in 
therapy-sensitive and therapy-resistant cells, we used a 16aa synthetic peptide 
containing Par-4 residues 68 to 73 or a 16aa VASA mutant containing the 
ALANAL sequence. As seen in Figure 2.6C, the 16aa peptide but not the mutant 
peptide induces apoptosis in both therapy-sensitive and therapy-resistant cancer 
cells.  
In order for the VASA domain in PAF to bind to the SPRY domain within Fbxo45 
it is essential for the extracellular PAF to enter the cells. To confirm this 
hypothesis A549TR (taxane resistant lung cancer cells) were treated with PAF-
His protein and immunocytochemical analysis was performed. The cells were 
stained with an anti-His antibody and were visualized using confocal microscopy. 
A549TR cells treated with heat denatured PAF-His protein were used as the 
control group. As seen in Figure 2.6D only the active PAF-His protein (stained 
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green) was able to enter the cells whereas the inactivated control did not enter 
the cells. The data indicate the extracellular PAF actively enters cells in order to 
induce apoptosis. 
Extracellular Par-4 is known to induce apoptosis by binding to GRP78 at the cell 
surface. PAF is able to induce apoptosis in Par-4 resistant cell types that display 
low levels of cell surface GRP78 indicating the action of PAF is independent of 
GRP78. To directly verify the GRP78 independent action of PAF, we transfected 
Par-4 null MEFs with vector, Par-4 and PAF and the CM of these transfected 
cells was applied to A549 and H460 cells in the presence of antibodies to Par-4 
or GRP78. As seen in Figure 2.6E, the Par-4 antibody successfully inhibited 
apoptosis by both PAF and Par-4. The GRP78 antibody was unable to inhibit 
apoptosis in PAF-treated cells but it significantly reduced apoptosis in Par-4 
treated cells, thereby confirming that PAF induced apoptosis independently of 
cell surface GRP78.  
I hypothesized that upon PAF treatment, PAF translocates into the cells and 
sequesters the E3 ubiquitin ligase Fbxo45, thereby preventing the degradation of 
Par-4. Lack of degradation should result in increased levels of Par-4 protein 
within PAF treated cells. This hypothesis was tested, as shown in Figure 2.6E. 
First PAF was ectopically expressed in the H460 and A549TR cells and the cells 
were lysed. The protein lysates were resolved using SDS-PAGE and subjected 
to Western blot analysis. Cells were transfected with the PAF expression 
construct showed increased levels of full length Par-4 in comparison to the vector 
transfected group, suggesting that the degradation of Par-4 was significantly 
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reduced in the presence of PAF. The finding that PAF is able to enter the cells 
and induce apoptosis by preventing Par-4 degradation was further corroborated 
as follows. The CM from Par-4 null MEF’s which were transfected with an 
overexpression construct of PAF or vector control, was applied to the A549TR 
and H460 cells that were pretreated with either vehicle or CHX (10 µg/ml) for 30 
minutes. The CM from the transfected Par-4 null MEFs was applied to the lung 
cancer cells in combination with vehicle or CHX (10 µg/ml) for total of 5 h. The 
A549TR and H460 cells were denatured and Western blot analysis was carried 
out. As seen in Figure 2.6F, only the cells treated with the PAF-containing CM 
showed an elevation in the full length Par-4 levels compared to the vector control 
treatment group. The Par-4 stabilization effect displayed by the application of the 
PAF-containing CM was further enhanced in the presence of CHX, which inhibits 
de novo protein synthesis. Collectively these results indicate that application of 
PAF extracellularly facilitates the stabilization pf Par-4 by preventing degradation 
of Par-4.  
To verify the direct binding of PAF to Fbxo45, A549TR cell lysates were 
incubated with the anti-Fbxo45 antibody either in the presence or absence of 
PAF-His peptide and incubated at 4°C overnight. The antibody associated 
protein complexes were pulled down using magnetic protein A/G beads (to 
capture the His residues in PAF-His), and subjected to Western blot analysis; for 
Par-4. In the sample that was incubated with PAF, we noted that the Fbxo45 
antibody pulled down both PAF and full length Par-4 (Figure 2.6H). On the other 
hand, Par-4 but not PAF was pulled down in the control sample. Interestingly, 
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there was a significant decrease in Par-4-Fbxo45 binding in the presence of the 
PAF peptide compared to the sample without PAF treatment. These findings 
indicate that the VASA domain within PAF acts as decoy and competes with Par- 
4 for binding to the SPRY domain within Fbxo45. 
Finally, to test the efficacy of PAF in a physiological setting, 
immunocompromised mice were injected intravenously with 0.4x106 LLC-1 cells 
through the tail vein followed by an i.v. tail vein injection of the PAF-His peptide 
(250 µg). The tumors were allowed to grow for a period of 16 days followed by 
humane euthanasia. The lungs were removed, stained with India ink and the 
tumors nodules were counted with the aid of a dissecting microscope. The data 
clearly indicate a significant inhibition of tumor growth in the PAF-His treated 
animals compared to vehicle control (Figure 2.6I). These data demonstrate that 
PAF is capable of inducing tumor inhibition in vivo and the animals did not 
suffer any toxicity from the administration of PAF, consistent with our 
observations that PAF selectively kills cancer cells and does not induce 
apoptosis in normal cells. 
45 
46 
 
A549+A549TRGFP Mixed 
A549  
A549TRGFP  
**
p < 0.0001 
C 
47 
Figure 2.1: Tumor cell heterogeneity permits cancer therapeutics to 
overcome therapy resistance 
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(A) Paclitaxel induced apoptosis in paclitaxel-resistant cells co-cultured 
with paclitaxel-sensitive cells. A549/GFP cells or A549TR/RFP cells 
were grown separately (right panels) or co-cultured as a 1:1 mixture of 
A549/RFP and A549TR/GFP cells (0.1 x 106 each) (left panel), and 
treated with paclitaxel (25 nM) or vehicle (V) for 24 h. The cells were 
then scored for apoptosis by DAPI. Note that both A549/GFP (thin arrow) 
and A549TR/RFP (thick arrow) underwent apoptosis when treated with 
paclitaxel in co-cultures, but only A549/GFP and not A549TR/RFP cells 
showed apoptosis when treated with paclitaxel in separately grown 
cultures. 
(B) Paclitaxel induces paracrine apoptosis in paclitaxel-resistant cells. 
A549/GFP cells or A549TR/RFP cells (1 x 106 each) were treated with 
paclitaxel (25 nM) or vehicle for 24 h. The conditioned medium (CM) from 
these treated cells was transferred to untreated A549TR/RFP cells, and 24 
h later, the A549TR/RFP cells were scored for apoptosis. 
(C) Paclitaxel induces apoptosis in paclitaxel-resistant cells within tumors 
containing paclitaxel-sensitive cells.  A549 cells, A549TR/RFP cells or 
a 1:1 mixture (2 x 106 cells of each) of these two cell lines were injected 
into the flanks of nude mice. When the tumors had grown to 3-mm 
diameter, the mice were injected i.p. with paclitaxel (10 mg/kg body weight) 
or vehicle.  Six mice were used for each treatment group.  After humanely 
killing the mice, tumor sections were scored for apoptosis by TUNEL 
assays.    
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(D) Unbiased screen links apoptosis to Par-4 like secreted factor. A549 cells 
were treated with paclitaxel (25 nM) for 16 h. The CM from A549 cells was 
transferred to A549TR cells for 24 h in the presence of antibodies against 
TRAIL, GDF15, Par-4, Maspin, IGFBP3 or control IgG. The cells were then 
scored for apoptosis. 
(A, B, C) Asterisk (*) or (**) indicates statistical significance (P < 0.02) by the 
Student t test. 
(D) (***) indicates that the indicated treatments are significantly (P < 0.001) more 
effective than their respective control groups based on Student t test. 
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Figure 2.2: Identification of the Par-4-like candidate factor involved in 
paracrine apoptosis of diverse therapy-resistant cancer cells  
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(A) The 15 kDa amino-terminal fragment of Par-4 produced by paclitaxel-
sensitive A549 cells treated with paclitaxel is involved in paracrine 
apoptosis of paclitaxel-resistant A549TR cells. A549 cells were treated 
for 24 h with vehicle (V) or paclitaxel (PCT, 25 nM) to induce apoptosis, 
and lysate and CM from the cells were analyzed by Western blot analysis. 
The CM from the vehicle treated cells or PCT treated cells was applied to 
the PCT-resistant A549TR cells for 24 h. As controls the A549 and 
A549TR cells were treated with vehicle (V) or PCT for 24 h. The cells were 
scored for apoptosis. 
(B) The 15 kDa amino-terminal fragment of Par-4 produced by TRAIL-
sensitive PC-3 cells treated with TRAIL is involved in paracrine 
apoptosis of TRAIL-resistant DU145 cells. PC-3 cells were treated or 
24 h with vehicle (V) or TRAIL (100 ng/ml) to induce apoptosis, and the 
lysate and CM from the cells were analyzed by Western blot analysis. 
The CM from the vehicle treated cells or TRAIL treated cells, was applied 
to TRAIL-resistant DU145 cells for 24 h. As controls, PC-3 and DU145 
cells were treated with vehicle (V) or TRAIL (100 ng/ml) for 24 h. The cells 
were scored for apoptosis.   
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(C) The 15 kDa amino-terminal fragment of Par-4 produced by 
bicalutamide-sensitive LNCaP cells treated with bicalutamide is 
involved in paracrine apoptosis of bicalutamide-resistant DU145 
cells. LNCaP cells were treated for 24 h with vehicle (V) or bicalutamide 
(BIC, 70 µM) to induce apoptosis, and the lysates and CM from the cells 
was analyzed by Western blot analysis. The CM from the vehicle treated 
cells or BIC treated cells, was applied to BIC-resistant DU145 cells for 24 
h. As controls, LNCaP and DU145 cells were treated with vehicle (V) or
BIC (70 µM). The cells were scored for apoptosis. 
(D) The 15 kDa amino-terminal fragment of Par-4 produced by PLX-4720-
sensitive Mel1617 cells treated with PLX-4720 is involved in 
paracrine apoptosis of PLX-4720-resistant Mel1617BR cells. Mel1617 
cells were treated for 24 h with vehicle (V) or PLX-4720 (PLX, 2.5 µM) to 
induce apoptosis and the lysate and CM) was analyzed by Western blot 
analysis. The CM from the vehicle-treated cells (V/CM) or PLX-4720-
treated cells (PLX/CM) was applied to the PLX-4720-resistant Mel1617BR 
cells for 24 h.  As controls, Mel1617 and Mel1617BR cells were treated 
with vehicle (V) or PLX (2.5 µM). The cells were scored for apoptosis. 
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(E) Chemotherapeutic agents result in Par-4 cleavage to produce the 
15kDa fragment. H460 cells were treated with TRAIL (100 ng/ml) for 6 h 
and Doxorubicin for 16 h. The CM and whole cell lysates were subjected 
to Western blot analysis. 
(A-D)  The CM in each case was combined with antibody (Ab) targeting the 
N- or C-terminus for Par-4 or control IgG, and apoptotic cells were scored. 
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Figure 2.3: Identification of PAF 
58 
(A) (Left Panel) Production of the 15 kDa and 25 kDa fragments was not 
dependent on new gene expression. H460 cells were pre-treated with 
cycloheximide (CHX, 20 µg/ml) for 30 minutes and then treated with 
TRAIL (100 nM) for 6 h. Whole-cell lysates were subjected to Western 
blot analysis.  
(Right Panel) Identification of the 15 kDa and 25 kDa bands as the 
products of 1-131aa and 332aa, respectively, of Par-4. H460 cells 
were transfected with expression constructs for 1-131aa Par-4, 132-
340aa Par-4, GFP, or Par-4-CT-GFP or vector as a control, and whole-
cell lysates were subjected to Western blot analysis.  
(B) The 25 kDa and 15 kDa fragments are produced by caspase-
dependent cleavage of Par-4 at its D131 residue. (Left Panel) H460 
cells were treated with vehicle, TRAIL or doxorubicin or transfected with 
vector or Par-4 expression construct, in the presence or absence of z-
VAD-fmk. Whole-cell lysates were subjected to Western blot analysis.  
(Right Panel) H460 cells were transfected with expression constructs for 
Par-4, 1-131aa or 132-340aa deletion mutants of Par-4, or D131A point 
mutant of Par-4 or vector control. Whole cell lysates were collected and 
subjected to Western blot analysis.       
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(C) Par-4 cleavage occurs at the D131 residue in a caspase-dependent 
manner.  
PC-3 cells (left panel) or H460 cells (right panel) were transfected with 
expression constructs for Par-4, Par-4131A mutant or vector for 24 h and 
subsequently treated with TRAIL for 6 h. Whole cell lysates were 
prepared and subjected to Western blot analysis. 
(D) H460 cells (left Panel) were treated with TRAIL (100 ng) and whole cell 
lysates were collected at 30 min time intervals up to 4 h and subjected to 
Western blot analysis.  
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Figure 2.4: PAF induces apoptosis selectively in cancer cells 
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(A) Recombinant PAF induces apoptosis specifically in cancer cells. A 
panel of cancer and normal cell lines were treated with recombinant TRX, 
TRX-Par-4 or TRX-PAF (100 nM each) for 24 h, and cells were scored for 
apoptosis. 
(B)  PAF induces apoptosis in specifically cancer cells but not in normal 
cells. 3T3 cells were transfected with expression constructs for Par-4, 
PAF or vector. The CM was applied to H460, A549 and LNCaP cancer 
cells as well as normal HEL cells, NIH 3T3 and MEFs. After 24 h the cells 
were scored for apoptosis. 
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Figure 2.5: Mechanism of PAF induced apoptosis 
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(A)  PAF induced apoptosis is dependent on caspase-8 and caspase-
3. Mouse embryonic fibroblasts (MEFs) were transfected with vector,
expression constructs for Par-4 or PAF and the CM from PAF 
transfected cells was applied to A549 cells in the presence of pan-
caspase inhibitor (z-VAD-fmk), or inhibitors of caspase-3, caspase-8, 
or caspase-9, respectively. The A549 cells were scored for apoptosis. 
(B)  PAF-induced apoptosis is dependent on FADD and caspase-8. 
PC-3 parent cells, PC-3 cells expressing dnFADD, PC-3 cells 
expressing FLIP were treated with recombinant TRX, TRX-Par-4 or 
TRX-PAF (100 nM each) for 24 h, and cells were scored for apoptosis.  
(C)  PAF induced apoptosis is dependent on intracellular Par-4. A549 
cells transfected with shRNA to Par-4 or shControl RNA were treated 
with TRX, TRX-Par-4, or TRX-PAF (100 nM each) for 24 h. The cells 
were subjected to Western blot analysis for Par-4 to confirm 
knockdown of Par-4. Nuclei were revealed with DAPI and apoptotic 
cells were scored. 
(D)  Intracellular Par-4 is not essential for PAF induced apoptosis. 
A549 siRNA Par-4 knock down cells were treated TRX, TRX-Par-4, or 
TRX-PAF (100 nM each) for 24 h. The cells were subjected to 
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immunocytochemical analysis (ICC) for Par-4 to confirm knockdown of 
Par-4. Nuclei were revealed with DAPI and apoptotic cells were 
scored. 
(E)  The minimum domain of PAF is essential for apoptosis induction. 
MEFs were transfected with deletion mutants of PAF and the CM was 
applied to A549 cells for 24 h. The A549 and PC-3 cells were scored 
for apoptosis. The PC-3 cells were treated and scored for apoptosis by 
Dr. Ravshan Burikhanov. 
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Hypothesis for PAF induced apoptosis: (Left) Par-4 binds to Fbxo45 and is 
targeted for degradation by the Ubiquitin Proteasomal Pathway. Upon treatment 
of cancer cells with PAF, the VASA domain within PAF acts as a decoy and 
sequesters Fbxo45, thereby disrupting Fbxo45-Par-4 binding. This elevates 
intracellular Par-4 levels and induces apoptosis in the cancer cells. 
Figure 2.5.1: Hypothesis for PAF induced apoptosis 
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Figure 2.6: PAF sequesters Fbxo45 and prevents Par-4 degradation 
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(A)  The VASA domain is necessary for PAF induced apoptosis   
H460 cells were transfected with expression constructs for PAF, 
PAF/ALANAL mutant, and vector for control for 24 h. The CM from the H460 
transfectants was transferred to cancer cells for 24 h and the cells were 
scored for apoptosis.  The Western blot for the H460 transfection was 
performed by Dr. Ravshan Burikhanov 
(B)  PAF induces apoptosis in a Par-4 dependent manner Par-4 null MEFs 
were transfected with expression constructs for Par-4, PAF, Par-4/ALANAL 
mutant, PAF/ALANAL mutant or vector. The CM from the Par-4 null cells was 
applied to A549 cells stably transfected with Par-4 shRNA or Control shRNA 
and the cells were scored for apoptosis following 24 hours of treatment. 
(C)  The VASA domain is critical for PAF induced apoptosis A549 and H460 
cells were treated with a 16 aa synthetic peptide containing the VASA 
(ELNNN) domain or the mutant (ALANA) domain at 100nM concentration and 
the cells were stained and scored for apoptosis. 
(D) PAF enters the cells to induce apoptosis. A549TR lung cancer, and 
normal Beas2B and wild type mouse embryonic fibroblasts (WT MEFs) cells 
were treated with PAF-His protein (100 nM) or heat inactivated PAF-His 
(used as control). The cells were fixed and stained with an anti-His antibody 
and imaged using a confocal microscope. This experiment was performed by 
Dr. Ravshan Burikhanov. 
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(E) PAF induced apoptosis is independent of cell surface GRP78. Par-4 null 
MEF’s were transfected with vector, Par-4 or PAF constructs. The CM from 
the MEFs was applied to A549 and H460 cells in the presence of Control IgG 
or Par-4 or GRP78 antibody. The cells were fixed and stained with DAPI and 
were scored for apoptosis. The top panel shows expression of Par-4 and 
PAF in the Par-4 null MEFs in lysates and CM subjected to SDS page and 
Western blot analysis.  
(F) PAF prevents the degradation of intracellular Par-4. H460 and A549TR 
and cells were transfected with vector, Par-4 or PAF overexpression 
constructs and the lysates were resolved using SDS Page followed by 
Western blot analysis. 
(G) Extracellular PAF prevents the degradation of intracellular Par-4. Par-4 
null MEF’s were transfected with vector, Par-4 or PAF constructs and the CM 
was applied to H460 and A549TR cells. The cells were pretreated with 
vehicle or Cycloheximide (CHX) at 10 µg/ml for 30 minutes followed by 
addition of CM. The cells were treated with CM in combination CHX for a 
total of 5 h; lysates were collected and subjected to SDS-PAGE and Western 
blot analysis. This experiment was performed by Ms. Nidhi Shukla. 
(H) PAF competes with Par-4 and reduces its binding to Fbxo45. A549TR 
cells were lysed and the lysates were subjected to immunoprecipitation. The 
samples were incubated with Fbxo45 antibody in the presence or absence of 
PAF-His peptide (1.5 µg). Next, samples were pulled down using magnetic 
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protein A/G beads and were resolved using SDS-PAGE and Western blot 
analysis was performed using the Par-4 antibody.  
(I) PAF inhibits metastatic tumor growth in vivo. NSG mice were injected i.v. 
with 0.4x106 LLC-1 cells. PAF-His protein or vehicle control was injected 5 
h later by the i.v. route. A total of 250 µg of His-PAF protein was given. The 
animals were sacrificed and the lungs were excised 18 days post injection 
of cells. The lungs were injected with India ink and the tumor nodules were 
counted.    
(E, I) Asterisk (*) indicates statistical significance (P < 0.02) based on Student’s t 
  test 
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CHAPTER THREE: DISCUSSION ANF FUTURE DIRECTIONS 
Heterogeneity of tumors poses a significant challenge to cancer therapy due to 
the existence of drug resistant cell populations. Our present study indicates that 
treatment of therapy-sensitive cancer cells with chemotherapeutic agents leads 
to apoptosis of therapy-resistant cancer cells in culture. Importantly, growth of 
therapy-resistant tumor cells was also inhibited by therapy that was administered 
to xenografts containing a heterogeneous mix of both therapy-sensitive and 
therapy-resistant tumor cells. By contrast, xenografts containing only therapy-
resistant tumors were not inhibited by the same therapeutic regimen. These 
observations supported the release of a factor(s) from the therapy-sensitive 
tumor cells to induce apoptosis in therapy-resistant tumor cells leading to tumor 
growth inhibition. Although previous studies indicate that dying cells release 
tumor cell-inhibitory factors, the precise factor(s) released by during the process 
has been elusive (Hou et al., 2013). We identified this factor as PAF, a previously 
unidentified 15 kDa caspase-cleaved fragment of the tumor suppressor Par-4. 
PAF is produced by cleavage of Par-4 at its D131 residue and is preferentially 
shed into the tumor cell microenvironment for paracrine apoptosis of both 
therapy-sensitive and therapy-resistant tumor cells. Most importantly, we 
identified the VASA domain of Par-4 that resides within PAF as an essential 
domain for the apoptotic action of PAF. Intracellular Par-4 is normally 
sequestered and degraded by the ubiquitin ligases. Our studies indicate that PAF 
translocates into the cells and serves as a decoy by binding, via its VASA 
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domain, to ubiquitin ligases such as Fbxo45, and thereby releases intracellular 
Par-4 for apoptosis of cancer cells. Interestingly, extracellular PAF induces 
apoptosis in a wide array of cancer cells, including therapy-resistant clones, but 
not in normal cells. Thus, cancer therapeutics that target sensitive populations of 
tumor cells exhibit a built-in mechanism for targeting therapy-resistant cells via 
cleavage of Par-4 and release of PAF. However, as tumor cells ultimately 
develop resistance to therapy, our ongoing studies are directed toward 
understanding the parameters that may contribute to resistance to PAF-mediated 
apoptosis, in an effort to harness PAF to overcome tumor resistance to therapy. 
PAF extends the target range of Par-4 to therapy-resistant cancer cells 
Tumor heterogeneity is a roadblock in the treatment of cancer. However, as 
sensitive cells within the population are expected to release diverse factors when 
treated with cancer therapeutics, we hypothesized that such factors may perturb 
the resistant population. Rather unexpectedly, we identified PAF, a fragment of 
Par-4 shed by therapy-sensitive cancer cells undergoing apoptosis that can kill 
both therapy-sensitive and therapy-resistant cancer cells. The target range of 
PAF is not limited to any single type of cancer. We noted that lung cancer cells 
resistant to taxanes, prostate cancer cells resistant to TRAIL or bicalutamide, and 
melanoma cells resistant to the mutant-BRAF-inhibitor were sensitive to 
apoptosis by PAF. Interestingly, when Par-4 is intact, it does not induce cell 
death in most of the therapy-resistant lung or prostate cancer cells. In fact, the 
VASA domain within the PAF residues in intact Par-4 compromises the stability 
of Par-4 by serving as a binding motif for ubiquitin ligates such as FBXO45 that 
79 
degrade Par-4. Our studies indicate that when Par-4 is naturally cleaved by 
caspase action to produce PAF, or when recombinant PAF protein is provided 
exogenously to cancer cells, it can enter the cells and stabilize Par-4. We further 
showed that PAF competes with the binding of ubiquitin ligase Fbxo45 to Par-4, 
thereby allowing Par-4 to stay physically and functionally intact and induce 
apoptosis of the cancer cells, regardless of whether they are sensitive or 
resistant to Par-4.  
The VASA domain of PAF interacts with ubiquitin ligase complexes 
Our present studies indicated that the VASA domain located within PAF is 
important for competitive binding of PAF to Fbxo45, in order to release Par-4 for 
apoptosis. FBXO45 binds to the VASA domain of Par-4 via its SPRY module. 
Similarly, previous studies indicate that the SPRY domain of SSB family proteins 
(SSB-1, -2, and -4) binds to the VASA module of Par-4. SSB-1, -2, and -4 
associate with Elongin C through the BC box in the C-terminal SOCS box, and 
each of SSB-1, -2, and -4 was shown to form a multiprotein E3 ubiquitin ligase 
complex with Elongin B, Elongin C, Cul5, and a RING protein(Kamura et al., 
2004). Like many SOCS box-containing proteins, the SSB family proteins could 
function as receptors for the substrate proteins that are ubiquitinated by cullin-
based ubiquitin ligases (Kile et al., 2002).  
PAF induces apoptosis selectively in cancer cells 
It is particularly noteworthy that despite the ability of PAF to translocate into cells 
when provided exogenously, PAF induces apoptosis exclusively in cancer cells 
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but not in normal cells. This finding is consistent with the fact that ubiquitin 
ligases are elevated in cancer cells relative to normal cells (Mani and Gelmann, 
2005). Our previous studies showed that intracellular Par-4 must translocate to 
the nucleus to inhibit NF-κB activity. Accordingly, in the presence of PAF, 
intracellular Par-4 binding to ubiquitin ligases is blocked in cancer cells, so it 
readily enters the nucleus to inhibit NF-κB activity to induce apoptosis.  
PAF action in therapy-resistant tumors 
Chemotherapeutic regimens are highly toxic, which leads to a number of side 
effects and results in patient discomfort. To circumvent this issue, chemotherapy 
is often administered at high doses over short intervals to alleviate patient 
suffering. Our study suggests that cancer-therapeutics that can induce a pro-
apoptotic response in therapy-sensitive cancer cells may alter the tumor 
microenvironment, thereby making it conducive to apoptosis of therapy-resistant 
tumor cells. However, we noted that only about 40-50% of the cells in culture 
undergo apoptosis with PAF. This information implies that PAF is unable to 
achieve its full effect, perhaps due to several factors: (a) Proximity of the 
sensitive cancer cells to resistant cancer cells within the heterogeneous tumor 
architecture may influence the access of shed PAF protein to the resistant cells. 
(b) Rapid elimination of the sensitive cells with high doses of chemotherapy may 
lead to survival of therapy-resistant cells. Administering a lower, albeit 
therapeutic, dose of the chemotherapeutic agent would result in slower 
elimination of therapy-sensitive cells, and prolong the release of PAF. (c) About 
50-60% cells, which survive the effect of PAF, may be intrinsically resistant to 
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PAF. A recent study has indicates the emergence of therapy resistant clones 
within heterogeneous tumors owing to activation of cell survival kinases such as 
Akt1(Spagnolo et al., 2014) As Akt1 is known to bind to Par-4 and inhibit Par-4 
inducible apoptosis, emerging clones with elevated Akt1 activity may be resistant 
to PAF-induced apoptosis.  
Evolution and significance of the VASA domain in PAF 
We constructed a phylogenetic tree using the Constraint Based Alignment Tool 
(COBALT); the search was designed to look for conservation of the VASA like 
ELNNNL domain in PAF across a number of different vertebrates, ranging from 
zebrafish to humans. As seen in Figure 3.1, there is significant sequence 
conservation of the domain across many vertebrate species with almost 100% 
conservation in zebrafish, xenopus and also in evolutionarily ancient fish like the 
coelacanth. However there is a slight variation in the sequence when compared 
to rodents like mice and rats, as they differ in two amino acids. It is of particular 
interest to note, that in the great apes like chimpanzees, monkeys like rhesus 
monkeys (as well green and golden monkeys, not shown) and in humans the 
sequence shows 100% conservation. This kind of conservation highlights the 
significance of the VASA domain within Par-4 and PAF. In essence, this high 
level of conservation raises the possibility that the chronic accumulation of Par-4 
within certain tissues may be detrimental to the organism.  For instance, the brain 
plays a significant role in neurodegenerative diseases and evidence in literature 
suggests that increased Par-4 expression in the hippocampal neurons can lead 
to accumulation of the amyloid beta-protein leading to early onset Alzheimer’s 
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disease (Guo et al., 1998). There is also evidence linking increased expression of 
Par-4 in the substantia nigra of mice and monkeys to Parkinsons like pathology 
(Duan et al., 1999); as well Amyotrophic lateral sclerosis (ALS) due to the Par-4 
mediated degeneration of motor neurons (Pedersen et al., 2000). Moreover, 
inhibition of Par-4 in these conditions helps prevent further damage to the 
affected neurons (Duan et al., 1999; Xie et al., 2005). It is possible that the VASA 
domain was evolutionarily conserved to facilitate the clearance of Par-4 from 
these neurons by ubiquitin ligase dependent mechanisms, thereby maintaining 
cellular homeostasis and preventing neurodegeneration. Consistent with this 
hypothesis, the E3 ligase Fbxo45 which targets Par-4 for degradation was also 
initially identified in the brain and is a major player in normal brain development. 
These are intriguing questions that can be addressed in future studies. However, 
the very advantage provided by the VASA domain in neuronal maintenance, 
constitutes a weakness in the cancer setting as Par-4 downregulation can 
promote tumor growth and lead to poor prognosis and therapy resistance. 
Therefore, the discovery of PAF, offers a novel translational approach to 
circumvent this issue and overcome therapy resistance. 
FUTURE DIRECTIONS 
My studies have identified a novel factor that is released from apoptotic cells 
which has not only has the ability to kill therapy resistant cancer cells, but does 
so in a cancer specific manner. The cancer specificity arises from multiple factors 
such as the overexpression of ubiquitin ligases in cancer cells, the dependence 
on Par-4 for apoptosis induction and also the ability of PAF to enter cancer cells. 
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I also observed that exogenously applied PAF only enters cancer cells while it 
does not enter the normal cells. The underlying reasons for the cancer specific 
entry of PAF into the cells remains unidentified. The fact that PAF is able to 
translocate specifically into cancer cells, invokes several possibilities. First, the 
participation of an exciting class of molecules termed as Cell Penetrating 
Peptides (CPPs) needs to be tested. Although PAF is larger than the classical 
CPPs which are usually 30-35 amino acids long, the active motif within PAF lies 
within this range (as demonstrated by the results with the 16aa peptide in Figure 
2.6C). A number of mechanisms like pore formation, membrane thinning model 
or endocytosis are responsible for the uptake of such peptides (Madani et al., 
2011). The cancer specific uptake of PAF suggests that endocytosis, which is an 
active process, might be a possible means of uptake into the cells. Endocytosis 
is often mediated by clathrins or caveolins at the cell membrane. These protein 
groups, more specifically caveolin-1, are often upregulated in cancers and are 
known to impact cancer prognosis (Ho et al., 2008; Thompson et al., 2010). 
Much work needs to be done to identify the exact class of molecules that play a 
role in the cancer specific uptake of PAF and their differential status in normal 
cells.  
Another aspect of PAF induced apoptosis that remains to be studied is its role in 
the treatment of primary brain tumors or brain metastases in a physiological 
setting. Whether PAF crosses the blood brain barrier needs to be investigated; it 
would be important  to test the effect PAF treatment on glioblastomas in which 
the expression of the SAC domain of Par-4 acts as a potent inhibitor of glioma 
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stem cells (Liu et al., 2014).  We observed that PAF liberates Par-4 from Fbxo45 
mediated degradation and that allows Par-4 to induce apoptosis in the cancer 
cells. However, we know little about the mechanism of apoptosis that is 
employed by the free intracellular Par-4 in the different therapy resistant cancer 
cells. Par-4 induces apoptosis by activation of the FADD-caspase 8 pathway, 
thus generating more PAF in the process, but intracellular Par-4 released by PAF 
treatment could also bind to ζPKC in the cytoplasm and inhibit its prosurvival 
activity and thereby exert its pro-apoptotic effects (Diaz-Meco et al., 1996). 
These mechanisms need to be evaluated in the diverse cancers that are 
sensitive to PAF induced apoptosis. 
Although we have identified the VASA domain within PAF as a target for the E3 
ubiquitin ligase Fbxo45, there could possibly be other binding partners for PAF 
within the cytoplasm. We believe that the sequence of PAF is not usually 
exposed when it is a part of full length Par-4 and its domains are not available for 
binding to other cellular proteins. But, in the event of caspase cleavage, when 
PAF is released from Par-4 there is a distinct possibility that other proteins that 
may or may not induce other ubiquitin ligases might bind to PAF and regulate its 
pro-apoptotic effect within cancer cells. Although this is speculative at this time, 
further pull down studies followed by mass spectrometry could expose those 
binding partners and offer additional insights to aid cancer therapeutics. 
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therapy-sensitive and therapy-resistant cancer cells, causing growth inhibition of 
heterogeneous tumors containing therapy-resistant tumor cells. The action of 
PAF was attributed to its ability to translocate into cells and bind, via its VASA 
domain, to the SPRY domain of ubiquitin ligases such as Fbxo45. Thus, PAF 
acts as a decoy to rescue Par-4 from ubiquitin ligase-dependent degradation, so 
that Par-4 can induce apoptosis of cancer cells. As the SPRY domain is a protein 
interaction module discovered thus far in a large number of human and murine 
proteins, PAF or Par-4 may interact with a large family of proteins with 
biochemical and biological functions extending beyond those associated with 
protein degradation.  Interestingly, PAF selectively induces apoptosis in cancer 
cells but not in normal cells, and this function of PAF can be harnessed to 
overcome therapeutic resistance in tumors. 
We can also test the efficacy of PAF in PDX models and combining it tumor 
infiltrating lymphocytes that are infected with PAF as it would provide 
information that would more clinically/physiologically relevant and could be a 
powerful therapeutic strategy. The release of PAF from cancer associated 
fibroblasts (CAFs) is an area that remains to be explored and could further 
highlight the importance of the tumor microenvironment in cancer treatment.
In summary, I have identified a caspase-cleaved fragment, PAF, of Par-4 that is 
naturally produced and shed into the microenvironment by diverse cancer cells 
undergoing apoptosis in response to chemotherapeutic agents. PAF kills both 
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Figure 3.1: Evolutionary conservation of the VASA domain in PAF 
The figure depicts the phylogenetic tree constructed for the VASA like ELNNNL 
domain found in Par-4/PAF. The conserved amino acids are shown in blue while 
the amino acids that are not conserved are shown in red.  
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Figure 3.2: Model for PAF induced apoptosis 
Therapy sensitive cells treated with chemotherapeutic agents undergo caspase 
activation leading to the cleavage of Par-4 to release PAF. The PAF released 
from the therapy sensitive cell is able to enter the surrounding therapy resistant 
cells and bind to the E3 ligase Fbxo45, thereby acting as a decoy for Par-4. 
Hence Par-4 is not degraded by the ubiquitin proteasome system and can induce 
apoptosis in the therapy resistant cells.   
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